Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case–control real-world study

References

• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020 Dec 31;383(27):2603–2615.
   PubMed Web of Science ®Google Scholar
• Palacios R, Patino EG, de Oliveira Piorelli R, et al. Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by sinovac – PROFISCOV: a structured summary of a study protocol for a randomised controlled trial. Trials. 2020 Oct 15;21(1):853.
   PubMed Web of Science ®Google Scholar
• Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021 Feb 20;397(10275):671–681.
   PubMed Web of Science ®Google Scholar
• Jalkanen P, Kolehmainen P, Hakkinen HK, et al. COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. Nat Commun. 2021 Jun 28;12(1):3991.
   PubMed Web of Science ®Google Scholar
• Sander AL, Yadouleton A, Moreira-Soto A, et al. An observational laboratory-based assessment of SARS-CoV-2 molecular diagnostics in Benin, Western Africa. mSphere. 2021 Jan 13;6:1.
   Web of Science ®Google Scholar
• Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 covid-19 vaccine against the B.1.351 variant. N Engl J Med. 2021 Mar 16;384(20):1885–1898.
   PubMed Web of Science ®Google Scholar
• Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK phase 3 trial [cited 2021 January 28]. Available from: https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates -893-efficacy-uk-phase-3.
   Google Scholar
• Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99–111.
   PubMed Web of Science ®Google Scholar
• Mahase E. Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant. Brit Med J. 2021 Feb 1;372:296.
   PubMed Web of Science ®Google Scholar
• Shinde V, Bhikha S, Hoosain Z, et al. Efficacy of NVX-CoV2373 covid-19 vaccine against the B.1.351 variant. N Engl J Med. 2021 May 20;384(20):1899–1909.
   PubMed Web of Science ®Google Scholar
• Gao Q, Bao L, Mao H, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020 Jul 3;369(6499):77–81.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang Y, Huang B, et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell. 2020 Aug 6;182(3):713–721.
   PubMed Web of Science ®Google Scholar
• Zhang YJ, Zeng G, Pan HX, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021 Feb;21(2):181–192.
   PubMed Web of Science ®Google Scholar
• Xia S, Duan K, Zhang Y, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. Jama. 2020 Sep 8;324(10):951–960.
   PubMed Web of Science ®Google Scholar
• Jara A, Undurraga EA, Gonzalez C, et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N Engl J Med. 2021 Jul 7. https://doi.org/https://doi.org/10.1056/NEJMoa2107715
   Web of Science ®Google Scholar
• Vaccines highly effective against hospitalisation from delta variant.
   Google Scholar
• Liu C, Ginn HM, Dejnirattisai W, et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell. 2021 Jun 17;184(16):4220–4236.
   PubMed Web of Science ®Google Scholar
• Chinese vaccine proves 79.34% effective against COVID-19 in phase-3 study. Available from: http://www.china.org.cn/china/2020-12/30/content_77064790.htm.
   Google Scholar
• A COVID-19 vaccine may be only 50% effective. Is that good enough? [cited 2021 June 20]. Available from: https://www.wbez.org/stories/a-covid-19-vaccine-may-be-only-50-effective-is-that-good-enough/d1fe8f3b-09c8-4064-a44f-5503debd28bd.
   Google Scholar
• Skowronski DM, Setayeshgar S, Zou M, et al. Single-dose mRNA vaccine effectiveness against SARS-CoV-2, including alpha and gamma variants: a test-negative design in adults 70 years and older in British Columbia, Canada. Clin Infect Dis. 2021 Jul 9;ciab616:1093.
   Google Scholar
• Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021 Jul 8;596(7871):276–280.
   PubMed Web of Science ®Google Scholar
• China is vaccinating a staggering 20 million people a day [cited 2021 June 20]. Available from: https://www.nature.com/articles/d41586-021-01545-3.
   Google Scholar
• Characterisation WHOWGotC, Management of C-i. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020 Aug;20(8):e192–e197.
   Web of Science ®Google Scholar
• Li Y, Zhou Y, Cheng Y, et al. Effectiveness of EV-A71 vaccination in prevention of paediatric hand, foot, and mouth disease associated with EV-A71 virus infection requiring hospitalisation in Henan, China, 2017-18: a test-negative case-control study. Lancet Child Adolesc Health. 2019 Oct;3(10):697–704.
   Google Scholar
• Puig-Barbera J, Arnedo-Pena A, Pardo-Serrano F, et al. Effectiveness of seasonal 2008–2009, 2009–2010 and pandemic vaccines, to prevent influenza hospitalizations during the autumn 2009 influenza pandemic wave in Castellon, Spain. A test-negative, hospital-based, case-control study. Vaccine. 2010 Nov 3;28(47):7460–7467.
   Web of Science ®Google Scholar
• Martinez-Baz I, Martinez-Artola V, Reina G, et al. Effectiveness of the trivalent influenza vaccine in Navarre, Spain, 2010–2011: a population-based test-negative case-control study. Bmc Public Health. 2013 Mar 6;13:191.
   PubMed Web of Science ®Google Scholar